Antibody drug conjugates in gastrointestinal cancers

This week’s podcast from VJOncology brings you key updates in antibody drug conjugates (ADCs) for gastrointestinal cancer. Our expert panel discusses the potential of ADCs targeting HER2, CMET, and CEACAM5 in gastric and colorectal cancers. Hear from experts Kohei Shitara (National Cancer Center Hospital East), Yelena Janjigian (Memorial Sloan Kettering Cancer Center), John Strickler (Duke Cancer Institute), and Scott Kopetz (MD Anderson Cancer Center) as they provide an overview of the latest in ADCs for gastrointestinal cancers. Highlights include novel treatment strategies in HER2-expressing gastric cancer, findings from the DESTINY-Gastric03 and ABBV-400 trials, and the role of CEACAM5-targeting ADCs in colorectal cancer.